EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs

Kirsten Boerngen, Yogini Patel, Melissa Pittorino, Céline E Toutain iD

Journal of Veterinary Pharmacology and Therapeutics · 2026

DOI: 10.1111/jvp.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2026. Verfasst von Kirsten Boerngen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Elanco Animal Health GmbH, Monheim am Rhein, Germany. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Pyrimidines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.4 to 4.0 mg/kg, and multiple dosing was evaluated with daily oral doses of 0.8 mg/kg. Serial blood samples were collected, and plasma concentrations of ilunocitinib were measured using a validated LC–MS/MS method. Pharmacokinetic samples were also collected in field trials. Intravenous administration resulted in low plasma clearance (0.437 L/h/kg), a volume of distribution of 1.58 L/kg, and a terminal half‐life of 4.4 h. Oral administration led to rapid absorption ( T max usually ranging between 1 and 4 h) and higher bioavailability in fed dogs (80%) compared to fasted dogs (61%). The prandial effect observed in laboratory studies with single doses was not clinically relevant under field conditions. Exposure increased less than proportionally with increasing doses. No clinically relevant accumulation was observed with 0.8 mg/kg daily dosing. No sex‐based differences were observed. Altogether, ilunocitinib pharmacokinetics support a once‐daily oral dosing in dogs. Minimal accumulation, also confirmed in long‐term studies, further supports the safety of ilunocitinib with a daily dosing regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsPyrimidinesAnimalsDogsMaleFemaleAdministration, OralHalf-LifeBiological AvailabilityArea Under CurveDose-Response Relationship, Drug

Stichwörter der Autor:innen

JAK inhibitorcanine atopic dermatitisdogilunocitinibpharmacokinetics

Substanzen

Janus Kinase InhibitorsPyrimidines

Autor:innen und Institutionen

  • Elanco Animal Health GmbH, Monheim am Rhein, Germany.
  • Elanco Animal Health, Yarrandoo R&D Centre, Kemps Creek, New South Wales, Australia.
  • Elanco Animal Health, Sèvres, France.

ORCID-Profile: Céline E Toutain

Zitieren

APA

Boerngen, K., Patel, Y., Pittorino, M., & Toutain, C. E. (2026). Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.70022

Vancouver

Boerngen K, Patel Y, Pittorino M, Toutain CE. Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs. Journal of Veterinary Pharmacology and Therapeutics. 2026. doi:10.1111/jvp.70022

BibTeX
@article{Boerngen2026,
  author = {Boerngen, Kirsten and Patel, Yogini and Pittorino, Melissa and Toutain, Céline E},
  title = {Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2026},
  doi = {10.1111/jvp.70022}
}
Kostenlos starten →